Analytical Data
-
Gene name
ACAA1
- Application
-
Alternative Names
ACAA; PTHIO; Peroxisomal 3-Oxoacyl-Coenzyme A Thiolase; Acetyl-CoA acyltransferase; Beta-ketothiolase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P09110
-
Expression Region
Gly182~Asn424
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACAA1, or Acetyl-CoA acyltransferase 1, is a key enzyme involved in the metabolic pathway of fatty acid oxidation, specifically in the peroxisomes and mitochondria. This enzyme catalyzes the conversion of acyl-CoA to 3-ketoacyl-CoA, an important step in the degradation of fatty acids. Mutations in the ACAA1 gene have been associated with various metabolic disorders, including peroxisomal biogenesis disorders and specific forms of acyl-CoA oxidation defects. The study of ACAA1-recombinant proteins has gained increased attention due to its potential implications in understanding these metabolic conditions and developing targeted therapies. By generating and characterizing recombinant ACAA1 proteins, researchers aim to elucidate the enzyme's structure, function, and regulatory mechanisms. Understanding these aspects is crucial for elucidating the pathological mechanisms underlying ACAA1-related disorders and exploring potential therapeutic strategies that could improve patient outcomes. Furthermore, recombinant ACAA1 proteins can serve as valuable tools in metabolic engineering and synthetic biology, enabling the development of bioindustrial applications that leverage fatty acid metabolism. Through comprehensive research on ACAA1, scientists hope to pave the way for innovative treatments for metabolic diseases and advance our understanding of lipid metabolism in human health.
